{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:10:23Z","timestamp":1788617423888,"version":"build-2803163510"},"reference-count":17,"publisher":"Japanese Urological Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2024,1,20]]},"DOI":"10.5980\/jpnjurol.115.21","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T22:12:21Z","timestamp":1737324741000},"page":"21-27","source":"Crossref","is-referenced-by-count":3,"title":["EFFICACY AND SAFETY OF ENFORTUMAB VEDOTIN IN ADVANCED UROTHELIAL CARCINOMA TREATMENT: AN INITIAL EXPERIENCE IN A SINGLE INSTITUTION","\u5f53\u9662\u306b\u304a\u3051\u308b\u8ee2\u79fb\u30fb\u9032\u884c\u6027\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u5bfe\u3059\u308bEnfortumab vedotin\u306e\u521d\u671f\u4f7f\u7528\u7d4c\u9a13"],"prefix":"10.5980","volume":"115","author":[{"given":"Kiyoaki","family":"Nishihara","sequence":"first","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kurose","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Suekane","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouta","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuaki","family":"Chikui","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei-Ichiro","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakiri","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetaka","family":"Suekane","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Igawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4001","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM and Conte PF: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 17, 3068-3077, 2000.","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF and Bajorin DF: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med, 376, 1015-1026, 2017.","DOI":"10.1056\/NEJMoa1613683"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M and Petrylak DP: Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med, 384, 1125-1135, 2021.","DOI":"10.1056\/NEJMoa2035807"},{"key":"4","unstructured":"4) EAU Guidelines: Muscle-invasive and Metastatic Bladder Cancer. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer (cited 2023-6-5)."},{"key":"5","unstructured":"5) NCCN Guidelines: Bladder Cancer Version 3. 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf (cited 2023-6-5)."},{"key":"6","unstructured":"6) \u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7de8: \u8180\u80f1\u764c\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\uff3b2019\u5e74\u7248\uff3d2022\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8. https:\/\/jua.members-web.com\/topics1\/uploads\/attach\/topics_20160401403139_221017163228.pdf (\u53c2\u7167 2023-6-5)."},{"key":"7","unstructured":"7) \u65e9\u5ddd\u9053\u592a\u90ce, \u99ac\u5834\u88d5\u5b50, \u6cb3\u91ce\u901a\u826f, \u9ad8\u6a4b\u613c\u4e00: \u521d\u56de\u6295\u4e0e\u5f8c\u3088\u308a\u751f\u3058\u305f\u6297\u4f53\u85ac\u7269\u8907\u5408\u4f53enfortumab vedotin\u306b\u3088\u308b\u76ae\u819a\u969c\u5bb3. \u65e5\u76ae\u4f1a\u8a8c, 132, 2689-2694, 2022."},{"key":"8","unstructured":"8) \u571f\u4e95\u4fca\u5f66, \u5c0f\u91d1\u4e38\u8302\u535a: Antibody-Drug Conjugates (ADCs) \u306e\u57fa\u790e\u3068\u81e8\u5e8a-\u56fa\u5f62\u304c\u3093\u3092\u4e2d\u5fc3\u306b-. \u764c\u3068\u5316\u7642, 48, 743-748, 2021."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Matsubara N, Yonese J, Kojima T, Azuma H, Matsumoto H, Powles T, Rosenberg JE, Petrylak DP, Matsangou M, Wu C, Campbell M and Yamashiro M: Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med, 12, 2761-2771, 2023.","DOI":"10.1002\/cam4.5165"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Lacouture ME, Patel AB, Rosenberg JE and O'Donnell PH: Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist, 27, e223-e232, 2022.","DOI":"10.1093\/oncolo\/oyac001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Mejia R and Nutman TB: Evaluation and Differential Diagnosis of Marked, Persistent Eosinophilia. Semin Hematol, 49, 149-159, 2012.","DOI":"10.1053\/j.seminhematol.2012.01.006"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Vlachou E, Matoso A, McConkey D, Jing Y, Johnson BA, Hahn NM and Hoffman-Censits J: Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature. Eur Urol Open Sci, 49, 100-103, 2023.","DOI":"10.1016\/j.euros.2023.01.002"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Spotten LE, Corish CA, Lorton CM, Ui Dhuibhir PM, O'Donoghue NC, O'Connor B and Walsh TD: Subjective and objective taste and smell changes in cancer. Ann Oncol, 28, 969-984, 2017.","DOI":"10.1093\/annonc\/mdx018"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kaizu M, Komatsu H, Yamauchi H, Yamauchi T, Sumitani M and Doorenbos AZ: Characteristics of taste alterations in people receiving taxane-based chemotherapy and their association with appetite, weight, and quality of life. Support Care Cancer, 29, 5103-5114, 2021.","DOI":"10.1007\/s00520-021-06066-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Steinbach S, Hummel T, B\u00f6hner C, Berktold S, Hundt W, Kriner M, Heinrich P, Sommer H, Hanusch C, Prechtl A, Schmidt B, Bauerfeind I, Seck K, Jacobs VR, Schmalfeldt B and Harbeck N: Qualitative and Quantitative Assessment of Taste and Smell Changes in Patients Undergoing Chemotherapy for Breast Cancer or Gynecologic Malignancies. J Clin Oncol, 27, 1899-1905, 2009.","DOI":"10.1200\/JCO.2008.19.2690"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Berteretche MV, Dalix AM, d'Ornano AM, Bellisle F, Khayat D and Faurion A: Decreased taste sensitivity in cancer patients under chemotherapy. Support Care Cancer, 12, 571-576, 2004.","DOI":"10.1007\/s00520-004-0589-2"},{"key":"17","unstructured":"17) \u539a\u751f\u52b4\u50cd\u7701: \u91cd\u7be4\u526f\u4f5c\u7528\u75be\u60a3\u5225\u5bfe\u5fdc\u30de\u30cb\u30e5\u30a2\u30eb. \u85ac\u7269\u6027\u5473\u899a\u969c\u5bb3 (\u4ee4\u548c4\u5e742\u6708\u6539\u5b9a). https:\/\/www.mhlw.go.jp\/topics\/2006\/11\/dl\/tp1122-1s07.pdf. (\u53c2\u7167 2023-6-21)."}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/115\/1\/115_21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T04:33:33Z","timestamp":1737779613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/115\/1\/115_21\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.115.21","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]}}}